Cutler Group LP Athenex, Inc. Transaction History

Cutler Group LP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 04, 2022	SELL	$0.41 - $0.91 $41 - $91	-100 Reduced 11.11%	800 $0
Q3 2021 Oct 26, 2021	SELL	$2.97 - $4.84 $297 - $484	-100 Reduced 10.0%	900 $2,000
Q2 2021 Jul 19, 2021	SELL	$3.71 - $5.13 $14,101 - $19,499	-3,801 Reduced 79.17%	1,000 $4,000
Q1 2021 Apr 26, 2021	BUY	$4.08 - $14.75 $8,164 - $29,514	2,001 Added 71.46%	4,801 $20,000
Q3 2020 Oct 27, 2020	SELL	$10.26 - $14.55 $2,052 - $2,910	-200 Reduced 6.67%	2,800 $33,000
Q4 2019 Feb 06, 2020	BUY	$9.6 - $17.75 $21,120 - $39,050	2,200 Added 275.0%	3,000 $45,000
Q3 2019 Oct 28, 2019	BUY	$12.16 - $21.0 $7,296 - $12,600	600 Added 300.0%	800 $9,000
Q1 2019 May 10, 2019	BUY	$11.11 - $13.49 $2,222 - $2,698	200 New	200 $2,000

1.46M

Ticker ATNX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 156,790,000
Market Cap $1.57M
Description
Athenex, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of cancer. It operates through three segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform. The company's Orascovery product candidates include Oral paclitaxel and encequidar,...

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

Stay updated on Cutler Group LP with notifications on news.